Apollo economist warns: AI bubble now bigger than 1990s tech mania
Gain Therapeutics , Inc. (NASDAQ:GANX) announced Tuesday that it has amended its certificate of incorporation to increase the number of authorized shares of its common stock from 50 million to 100 million. The amendment was filed with the Secretary of State of Delaware following approval by a majority of stockholders during the company’s annual meeting, according to a press release statement and SEC filing.
At the annual meeting, stockholders voted on several proposals. Eight directors were elected to serve one-year terms, including Gene Mack, Dov Goldstein, M.D., Hans Peter Hasler, Khalid Islam, Ph.D., Gwen Melincoff, Claude Nicaise, M.D., Eric I. Richman, and Jeffrey Riley. Each nominee received between 8,273,363 and 10,079,460 votes in favor, with between 47,900 and 1,853,997 votes withheld. There were 8,426,391 broker non-votes for each nominee.
Stockholders also ratified the appointment of Ernst & Young AG as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote count was 18,033,714 in favor, 475,364 against, and 44,671 abstaining.
The proposal to increase the number of authorized shares of common stock was approved by 16,302,195 votes in favor, 2,239,298 against, and 12,258 abstentions.
Additionally, stockholders approved the potential adjournment of the annual meeting to a later date to allow for further solicitation of proxies if necessary, with 17,926,433 votes in favor, 607,272 against, and 20,043 abstaining.
The information in this article is based on statements from Gain Therapeutics, Inc. and details disclosed in a recent SEC filing. According to InvestingPro analysis, the company is scheduled to report its next earnings on August 7, 2025. Investors seeking deeper insights can access comprehensive financial health metrics and 8 additional ProTips through InvestingPro’s detailed research reports, which provide essential analysis for over 1,400 US stocks.
In other recent news, Gain Therapeutics has reported progress in its clinical-stage drug candidate, GT-02287, aimed at treating Parkinson’s disease. The company presented new preclinical evidence at the AD/PD™ 2025 International Conference, showcasing the drug’s potential to alleviate motor and complex behavioral deficits in animal models. These effects were observed to persist even after the withdrawal of the compound, indicating possible long-term benefits. Gain Therapeutics is currently conducting a Phase 1b clinical study to evaluate the safety, tolerability, and pharmacokinetics of GT-02287 in Parkinson’s patients. An early biomarker analysis from this study is anticipated in Q2 2025, with a full analysis expected by Q4 2025. The results will help in planning a Phase 2 study later in the year. The ongoing Phase 1b trial is taking place across seven sites in Australia and has shown a strong enrollment rate. The research has received financial support from several foundations and programs, including The Michael J. Fox Foundation for Parkinson’s Research. Gain Therapeutics is focusing on allosteric small molecule therapies, with GT-02287 targeting the restoration of glucocerebrosidase function, a critical enzyme impaired in Parkinson’s disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.